Gland Pharma Intrinsic Value
Gland Pharma intrinsic value. Gland Pharma (GLAND) median intrinsic value is ₹6049.73 from 10 valuation models (range ₹988–₹8232), vs current price ₹3292.90 — +83.7% upside (Trading Below Calculated Value), margin of safety 45.6%. For current market price and key ratios, visit Gland Pharma stock price NSE.
GLAND Valuation Methods Summary — DCF, Graham Number & P/E
Gland Pharma intrinsic value across 10 models vs current price ₹3292.90 — upside/downside and value range per method. Browse GLAND income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1550.56 | ₹1240.45 - ₹1860.67 | -52.9% | EPS: ₹70.48, Sector P/E: 22x |
| Book Value Method | asset | ₹8232.25 | ₹7409.03 - ₹9055.48 | +150.0% | Book Value/Share: ₹6092.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹6585.80 | ₹5927.22 - ₹7244.38 | +100.0% | Revenue/Share: ₹4477.65, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹6585.80 | ₹5927.22 - ₹7244.38 | +100.0% | EBITDA: ₹2212.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹6049.73 | ₹4839.78 - ₹7259.68 | +83.7% | CF Growth: 6.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹987.87 | ₹889.08 - ₹1086.66 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹1088.92 | ₹980.03 - ₹1197.81 | -66.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹6585.80 | ₹5927.22 - ₹7244.38 | +100.0% | ROE: 11.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹3108.41 | ₹2797.57 - ₹3419.25 | -5.6% | EPS: ₹70.48, BVPS: ₹6092.94 |
| Dividend Yield Method | dividend | ₹987.87 | ₹889.08 - ₹1086.66 | -70.0% | DPS: ₹20.00, Target Yield: 2.5% |
GLAND Intrinsic Value vs Market Price — All Valuation Models
Gland Pharma fair value range ₹988–₹8232 vs current market price ₹3292.90 across 10 valuation models. Analyse GLAND shareholder distribution to track promoter, FII and institutional holdings.
GLAND Intrinsic Value Analysis — Undervalued or Overvalued?
Gland Pharma median intrinsic value ₹6049.73, current price ₹3292.90 — Trading Below Calculated Value by 83.7%, margin of safety 45.6%.
What is the intrinsic value of GLAND?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Gland Pharma (GLAND) is ₹6049.73 (median value). With the current market price of ₹3292.90, this represents a +83.7% variance from our estimated fair value.
The valuation range spans from ₹987.87 to ₹8232.25, indicating ₹987.87 - ₹8232.25.
Is GLAND undervalued or overvalued?
Based on our multi-method analysis, Gland Pharma (GLAND) appears to be trading below calculated value by approximately 83.7%.
GLAND Financial Health — Key Ratios vs Industry Benchmarks
Gland Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 11.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 26.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GLAND Cash Flow Quality — Operating & Free Cash Flow
Gland Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,031 Cr | ₹1,031 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹915 Cr | ₹915 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹997 Cr | ₹123 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹364 Cr | ₹364 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹791 Cr | ₹292 Cr | Positive Free Cash Flow | 7/10 |